https://orcid.org/0000-0002-4881-720X
References
- Nijhof IS, van de Donk NWCJ, Zweegman S, et al. Current and new therapeutic strategies for relapsed and refractory multiple myeloma: an update. Drugs. 2018;78(1):19–37. doi: 10.1007/s40265-017-0841-y.
- Munshi NC, Anderson LD, Jr, Shah N, et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N Engl J Med. 2021;384(8):705–716. PMID: 33626253. doi: 10.1056/NEJMoa2024850.
- Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene autoleucel, an anti-B-cell maturation antigen chimeric antigen receptor T-cell therapy, for relapsed/refractory multiple myeloma: Cartitude-1 2-year follow-up. J Clin Oncol. 2023;41(6):1265–1274. doi: 10.1200/JCO.22.00842.
- Agha ME, Cohen AD, Madduri D, et al. CARTITUDE-2: efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy. J Clin Oncol. 39(15_suppl):8013–8013. doi: 10.1200/JCO.2021.39.15_suppl.8013.
- Karampampa K, Zhang W, Venkatachalam M, et al. Cost-effectiveness of idecabtagene vicleucel compared with conventional care in triple-class exposed relapsed/refractory multiple myeloma patients in Canada and France. J Med Econ. 2023;26(1):243–253. doi: 10.1080/13696998.2023.2173466.
- Kapinos KA, Hu E, Trivedi J, et al. Cost-effectiveness analysis of CAR T-cell therapies vs antibody drug conjugates for patients with advanced multiple myeloma. Cancer Control. 2023;30:10732748221142945. PMID: 36651055; PMCID: PMC9869188. doi: 10.1177/10732748221142945.
- Wu W, Ding S, Mingming Z, et al. Cost effectiveness analysis of CAR-T cell therapy for patients with relapsed/refractory multiple myeloma in China. J Med Econ. 2023;26(1):701–709. doi: 10.1080/13696998.2023.2207742.
- Gandhi UH, Cornell RF, Lakshman A, et al. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy. Leukemia. 2019;33(9):2266–2275. doi: 10.1038/s41375-019-0435-7.
- Petrou P. Is it a chimera? A systematic review of the economic evaluations of CAR-T cell therapy - an update. Expert Rev Pharmacoecon Outcomes Res. 2023. doi: 10.1080/14737167.2023.2214731.